Dassault Systèmes announced that it signed a definitive agreement to acquire ArisGlobal, the leading AI-native enterprise compliance platform for the Life Sciences industry. Under the terms of the agreement, Dassault Systèmes will acquire ArisGlobal for approximately $1.8 billion in cash at closing and up to $200 million in additional consideration linked to multi-year AI-related revenue milestones. The transaction was unanimously approved by the Board of Directors of Dassault Systèmes.

ArisGlobal’s leading AI-native enterprise compliance platform serves over 200 customers, including half of the Top 50 global biopharma companies as well as biotech, medtech, CROs and global health authorities. Its regulated core platform is deeply embedded within mission-critical operations and processes more than 12 million patient safety reports annually. ArisGlobal has over 1,300 employees globally and is expected to generate revenue of $175 million in 2026.

ArisGlobal operates in a highly resilient compliance market, projected to grow double-digits to reach $7.5 billion by 2030, and where software and AI are expected to capture an expanding share of total spend. Enterprise biopharma and MedTechs deploy ArisGlobal’s innovative technology solutions horizontally to track and manage global patient safety events, medical affairs, complex regulatory submissions, and quality processes. Its NavaX AI platform operationalizes clinical-grade AI at production scale within highly regulated environments. It delivers more than 30% productivity gains, helping customers automate complex processes, improve data quality, strengthen compliance and generate decision-grade intelligence across the product lifecycle.

Acquiring ArisGlobal advances Dassault Systèmes’ ambition to transform the Life Sciences industry by combining its unique domain expertise in discovery, clinical trials, manufacturing and quality with ArisGlobal’s leadership in regulated operations and real-world evidence management. Establishing a continuous evidence loop across the full therapy lifecycle creates a unified data and intelligence platform that industry will use to generate trusted outcomes, accelerate innovation, improve operational performance and develop safer therapies for patients.

Pascal Daloz, Dassault Systèmes’ Chief Executive Officer and Chairman of the Board, commented, “Today marks a major milestone in our ambition to transform the Life Sciences industry by connecting molecule, patient and real-world outcomes. Life Sciences is entering a new era of innovation - driven by artificial intelligence and the shift to precision medicine – while facing increasing operational complexity and regulatory scrutiny. Our vision to virtualize the industry has never been more relevant. By bringing together real-world evidence with our unique modeling and simulation expertise, this unified data and intelligence platform radically improves our ability to address persistent drug development challenges, allowing our customers to deliver safer, innovative therapies at a faster pace. We are excited to welcome ArisGlobal’s exceptional leadership team and talented people to the Dassault Systèmes family.”